Compare Vanguard Total Stock Market Index Fund ETF (VTI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Stock Market Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Total Stock Market Index Fund ETF trades at $369.4, while State Street SPDR S&P Biotech ETF trades at $154.37. Which is the better fit depends on your goals.
| VTI | XBI | |
|---|---|---|
52-Week High | $374.36 | $164.28 |
52-Week Low | $305.74 | $85.16 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTI trades at $366.25, down 0.21% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF offers broad exposure to the entire U.S. stock market with over 3,500 holdings and a low 0.03% expense ratio. Recent news highlights its role in long-term portfolios and inclusion in new tax-advantaged accounts, emphasizing diversification benefits.
Outlook remains positive for long-term investors due to historical performance and cost efficiency, but near-term risks include market volatility and potential underperformance if large-cap tech stocks weaken. The bearish technical setup suggests caution for short-term traders, while fundamentals support holding for wealth accumulation.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
